Authors
Latest:
Dr. O’Regan on the Utility of CDK4/6 Inhibitors in Breast CancerRuth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.
Latest:
Dr. Mehta on Frontline and Adjuvant Treatments in ESCCRutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy.
Latest:
Dr. Corcoran on Targeting HER2 Amplification in CRCRyan B. Corcoran, MD, PhD, discusses the presence of HER2 amplification in metastatic colorectal cancer.
Latest:
The Sustainability of Rising Drug Prices in OncologyRyan Bookout, PharmD, president, Hematology/Oncology Pharmacy Association, clinical pharmacist, Moffitt Cancer Center, discusses the sustainability of the field of oncology as drug prices continue to rise.
Latest:
ILI Provides Valuable Option for Inoperable Melanoma MetastasesAs melanoma becomes more prevalent and more lethal in the United States, a multidisciplinary approach for treating inoperable in-transit metastases has proved to be a viable and valuable option.
Latest:
Dr. Gentzler on Combination Therapies in NSCLCRyan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).
Latest:
Dr Sullivan on the Reduction of ctDNA With Tebentafusp in Metastatic Uveal MelanomaRyan J. Sullivan, MD, discusses the early reduction of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp and shares how these reductions could correlate with longer overall survival in patients with a best response of stable disease.
Latest:
Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLCPembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.
Latest:
Future Directions in Metastatic Uveal Melanoma TreatmentOmid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.
Latest:
Dr. Huey on Challenges Faced With Immunotherapy in HCCRyan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.
Latest:
Future Perspectives on the Treatment Landscape for CLLA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Latest:
Dr. Eckhardt on the Wnt Pathway in Colorectal CancerS. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.
Latest:
Dr. Davis on Immunotherapy in HER2-Positive Gastric/GEJ CancerS. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
Latest:
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual MeetingExperts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.
Latest:
Dr. Zafar on the Potential of Immunotherapy in Colorectal CancerS. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).
Latest:
Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple MyelomaSaad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.
Latest:
Dr Usmani on Approaching Treatment Decisions in High-Risk Multiple MyelomaSaad Z. Usmani, MD, MBA, FACP, discusses the complexity of approaching frontline treatment decisions in patients with high-risk multiple myeloma.
Latest:
The Next Chapter in RCC Recontextualizes Treatment ConsiderationsRenal cell carcinoma is one of the top 10 most common cancers, although incidence rates have been stable over the past decade. It is more common in men than women and rates are higher among African American, American Indian, and Alaska Native patient populations.
Latest:
Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.
Latest:
Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder CancerSaeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.
